UB Paderborn / Katalog / Suche / in CDI

Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome

Blood, 2014-03, Vol.123 (12), p.1864-1869

2014

Link zum Volltext

Verfügbarkeit prüfen

Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)

Haematologica (Roma), 2017-02, Vol.102 (2), p.235

2017

Link zum Volltext

Verfügbarkeit prüfen

Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry

Journal of clinical oncology, 2009-03, Vol.27 (9), p.1462-1469

2009

Link zum Volltext

Verfügbarkeit prüfen

Management of Persistent SARS-CoV-2 Infection in Patients with Follicular Lymphoma

Acta haematologica, 2022-01, Vol.145 (4), p.384-393

2022

Link zum Volltext

Verfügbarkeit prüfen

Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia

Annals of hematology, 2010-11, Vol.89 (11), p.1073-1080

2010

Link zum Volltext

Verfügbarkeit prüfen

Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. R-BMD Geltamo 08 Trial

Blood, 2012-11, Vol.120 (21), p.1639-1639

2012

Link zum Volltext

Verfügbarkeit prüfen

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations

Leukemia research reports, 2015, Vol.4 (2), p.64-69

2015

Link zum Volltext

Verfügbarkeit prüfen

Influence of Genetic Polymorphisms in CYP1A2, CYP2C19, CYP3A4, GSTP1, MDR1 and PSMB5 Genes in Toxicity and Response to Induction Therapy in Multiple Myeloma Patients Included in the Trial of the Spanish PETHEMA/GEM 05 for Newly Diagnosed MM Elderly Patients (Age 65 or More)

Blood, 2011-11, Vol.118 (21), p.1412-1412

2011

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

The lancet oncology, 2018-11, Vol.19 (11), p.1530-1542

2018

Link zum Volltext

Verfügbarkeit prüfen

Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma

European journal of haematology, 2016-05, Vol.96 (5), p.532-540

2016

Link zum Volltext

Verfügbarkeit prüfen

How to facilitate early diagnosis of CNS involvement in malignant lymphoma

Expert review of hematology, 2016-11, Vol.9 (11), p.1081-1091

2016

Link zum Volltext

Verfügbarkeit prüfen

Central nervous system relapse in diffuse large B cell lymphoma: Risk factors

Medicina clinica, 2016-01, Vol.146 (2), p.74-80

2016

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome

Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era

First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial

Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry

Management of Persistent SARS-CoV-2 Infection in Patients with Follicular Lymphoma

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials

R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

Risk Factors and Mortality of COVID‐19 in Patients With Lymphoma: A Multicenter Study

Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia

Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients with Follicular Lymphoma in Relapse or Refractory to First-Line Treatment with Immunochemotherapy. R-BMD Geltamo 08 Trial

Clinical and Biological Prognostic Factors Evaluation of Diffuse Large B-Cell Lymphoma Patients Relapsed or Refractory After Previous Line with Rituximab Plus Chemotherapy. Results of the Study PRO-R-IPI (NCT01369784)

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations

Influence of Genetic Polymorphisms in CYP1A2, CYP2C19, CYP3A4, GSTP1, MDR1 and PSMB5 Genes in Toxicity and Response to Induction Therapy in Multiple Myeloma Patients Included in the Trial of the Spanish PETHEMA/GEM 05 for Newly Diagnosed MM Elderly Patients (Age 65 or More)

Clinical Experience of Bendamustine Treatment for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Spanish Registry

Relapse after Autologous Stem Cell Transplant (ASCT) for Diffuse Large B Cell Lymphoma: Clinical Outcome and Prognostic Factors Affecting Long-Term Outcome

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Evaluation of Clinical and Biological Prognostic Factors in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients After Previous Treatment With Rituximab and Chemotherapy: Results of the PRO-R-IPI Study

Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma

How to facilitate early diagnosis of CNS involvement in malignant lymphoma

Central nervous system relapse in diffuse large B cell lymphoma: Risk factors

Suchergebnisse filtern